开发,合成和验证改进的c-Myc/Max抑制剂
Sümbül Yıldırım1,2,3, Fatih Kocabaş1,2, Arif Mermer4,5,6
1Department of Genetics and Bioengineering, Faculty of Engineering, Yeditepe University, Istanbul, Turkey.
Journal of cellular and molecular medicine
|April 3, 2024
概括
针对c-Myc/Max复合物的新型小化合物显示出强大的抗癌活性. 一种化合物c-Myc-i7在实验室中对前列腺和乳腺癌细胞表现出显著的选择性.
科学领域:
- 在瘤学瘤学.
- 药用化学 医学化学
- 分子生物学分子生物学
背景情况:
- 小化合物对于理解疾病病理生理学和开发新疗法至关重要.
- 针对特定的分子复合体,如c-Myc/Max,是癌症治疗中的一个有希望的策略.
研究的目的:
- 为了识别和描述抑制c-Myc/Max复合物的新型小化合物.
- 评估这些化合物的体外抗癌疗效和对各种癌症细胞系的选择性.
主要方法:
- 策划了针对c-Myc/Max复合体的各种新型小化合物的图书馆.
- 在PANC1,MCF7,DU-145和A549癌细胞系进行了体外试验,使用25μM剂量.
- 用IC50值来评估功效,并根据健康细胞评估选择性.
- 建立了与药物相似的模型.
主要成果:
- 确定了几种强大的c-Myc抑制剂,其IC50值低至1.6μM.
- 一些化合物在降低癌细胞活力方面比参考分子高出40倍.
- 化合物c-Myc-i7具有很高的选择性,对前列腺癌和乳腺癌细胞的偏好分别为37倍和59倍.
结论:
- 新型c-Myc抑制剂显示出作为有效的抗癌剂的巨大潜力.
- 使用这些抑制剂的各种瘤类型的体外研究可以导致开发突破性的癌症疗法.
- 已识别的化合物,特别是c-Myc-i7,需要进一步研究它们的治疗应用.
更多相关视频
10:09Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
Published on: January 7, 2019
8.3K
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
11.3K
相关概念视频
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
